OCUGEN, INC. Income Tax Credits and Adjustments
OCUGEN, INC. (OCGN) reported Income Tax Credits and Adjustments of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxCreditsAndAdjustments · last filed 2023-02-28
- OCUGEN, INC. income tax credits and adjustments for the quarter ending 2022-12-31 was $0.00.
- OCUGEN, INC. income tax credits and adjustments for the quarter ending 2021-12-31 was $0.00.
- OCUGEN, INC. income tax credits and adjustments for the quarter ending 2020-12-31 was $0.00.
- OCUGEN, INC. income tax credits and adjustments for fiscal 2022 was $0.00.
- OCUGEN, INC. income tax credits and adjustments for fiscal 2021 was -$52.00K.
- OCUGEN, INC. income tax credits and adjustments for fiscal 2020 was $0.00.
- OCUGEN, INC. income tax credits and adjustments for fiscal 2019 was $0.00.
| Period end | Income Tax Credits and Adjustments 3 month | Income Tax Credits and Adjustments 9 month | Income Tax Credits and Adjustments 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 | |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-08 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$52.00K 10-K · filed 2023-02-28 | |
| 2021-09-30 | -$52.00K 10-Q · filed 2022-11-08 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 | |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |